ProMIS Neurosciences (PMN) Competitors $0.72 +0.03 (+3.57%) Closing price 03:44 PM EasternExtended Trading$0.72 0.00 (-0.28%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMN vs. ADVM, CRDL, ATOS, LXEO, BDTX, ACOG, CRBU, CLYM, BMEA, and TCRXShould you be buying ProMIS Neurosciences stock or one of its competitors? The main competitors of ProMIS Neurosciences include Adverum Biotechnologies (ADVM), Cardiol Therapeutics (CRDL), Atossa Therapeutics (ATOS), Lexeo Therapeutics (LXEO), Black Diamond Therapeutics (BDTX), Alpha Cognition (ACOG), Caribou Biosciences (CRBU), Climb Bio (CLYM), Biomea Fusion (BMEA), and TScan Therapeutics (TCRX). These companies are all part of the "pharmaceutical products" industry. ProMIS Neurosciences vs. Adverum Biotechnologies Cardiol Therapeutics Atossa Therapeutics Lexeo Therapeutics Black Diamond Therapeutics Alpha Cognition Caribou Biosciences Climb Bio Biomea Fusion TScan Therapeutics Adverum Biotechnologies (NASDAQ:ADVM) and ProMIS Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings. Do analysts recommend ADVM or PMN? Adverum Biotechnologies presently has a consensus target price of $27.83, indicating a potential upside of 503.76%. Given Adverum Biotechnologies' higher probable upside, equities analysts plainly believe Adverum Biotechnologies is more favorable than ProMIS Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adverum Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83ProMIS Neurosciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of ADVM or PMN? 48.2% of Adverum Biotechnologies shares are owned by institutional investors. Comparatively, 50.1% of ProMIS Neurosciences shares are owned by institutional investors. 4.2% of Adverum Biotechnologies shares are owned by company insiders. Comparatively, 4.4% of ProMIS Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk and volatility, ADVM or PMN? Adverum Biotechnologies has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, ProMIS Neurosciences has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Does the MarketBeat Community favor ADVM or PMN? Adverum Biotechnologies received 366 more outperform votes than ProMIS Neurosciences when rated by MarketBeat users. However, 100.00% of users gave ProMIS Neurosciences an outperform vote while only 60.20% of users gave Adverum Biotechnologies an outperform vote. CompanyUnderperformOutperformAdverum BiotechnologiesOutperform Votes36960.20% Underperform Votes24439.80% ProMIS NeurosciencesOutperform Votes3100.00% Underperform VotesNo Votes Does the media favor ADVM or PMN? In the previous week, Adverum Biotechnologies had 2 more articles in the media than ProMIS Neurosciences. MarketBeat recorded 5 mentions for Adverum Biotechnologies and 3 mentions for ProMIS Neurosciences. Adverum Biotechnologies' average media sentiment score of 1.92 beat ProMIS Neurosciences' score of 0.30 indicating that Adverum Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adverum Biotechnologies 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive ProMIS Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is ADVM or PMN more profitable? Adverum Biotechnologies' return on equity of -65.14% beat ProMIS Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Adverum BiotechnologiesN/A -65.14% -40.52% ProMIS Neurosciences N/A -636.20%-130.32% Which has stronger valuation & earnings, ADVM or PMN? ProMIS Neurosciences has lower revenue, but higher earnings than Adverum Biotechnologies. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdverum Biotechnologies$1M95.90-$117.17M-$5.99-0.77ProMIS NeurosciencesN/AN/A-$13.21M-$0.10-7.25 SummaryAdverum Biotechnologies beats ProMIS Neurosciences on 10 of the 16 factors compared between the two stocks. Remove Ads Get ProMIS Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PMN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMN vs. The Competition Export to ExcelMetricProMIS NeurosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.70M$6.92B$5.63B$7.83BDividend YieldN/A2.73%4.57%4.00%P/E Ratio-7.257.1723.3318.67Price / SalesN/A220.97388.4691.04Price / CashN/A65.6738.1634.64Price / Book3.636.396.894.23Net Income-$13.21M$142.12M$3.20B$247.15M7 Day Performance12.40%-5.18%-3.02%-2.17%1 Month Performance-1.09%-7.49%1.63%-5.68%1 Year Performance-62.04%-8.78%9.74%-0.67% ProMIS Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMNProMIS Neurosciences0.7148 of 5 stars$0.73+3.6%N/A-60.0%$23.70MN/A-7.255Short Interest ↑ADVMAdverum Biotechnologies4.4138 of 5 stars$4.58-3.3%$27.83+508.4%-66.2%$94.23M$1M-0.76190Upcoming EarningsInsider TradeNews CoveragePositive NewsCRDLCardiol Therapeutics2.5854 of 5 stars$1.13-3.3%$8.40+642.6%-45.0%$93.44MN/A-2.9020ATOSAtossa Therapeutics1.8835 of 5 stars$0.74+1.6%$7.00+843.4%-61.8%$93.34MN/A-3.378Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageLXEOLexeo Therapeutics3.3338 of 5 stars$2.82-9.3%$23.80+744.0%-73.1%$93.25M$650,000.00-0.8958Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageBDTXBlack Diamond Therapeutics3.3483 of 5 stars$1.65-3.8%$14.60+787.5%-65.9%$93.21MN/A-1.2490Positive NewsACOGAlpha Cognition2.1142 of 5 stars$5.80+1.9%$20.00+244.8%N/A$92.92MN/A-2.27N/AUpcoming EarningsAnalyst UpgradeNews CoveragePositive NewsGap UpCRBUCaribou Biosciences3.3843 of 5 stars$0.99-2.7%$10.33+941.7%-80.7%$92.26M$9.99M-0.60100Short Interest ↓CLYMClimb Bio3.0265 of 5 stars$1.36-3.2%$10.00+638.0%N/A$91.09MN/A-0.649Earnings ReportAnalyst RevisionNews CoveragePositive NewsBMEABiomea Fusion3.0992 of 5 stars$2.51-0.6%$39.36+1,470.8%-83.8%$90.92MN/A-0.6350TCRXTScan Therapeutics3.6406 of 5 stars$1.60+3.2%$9.33+483.3%-82.5%$90.55M$2.82M-1.51100Short Interest ↓ Remove Ads Related Companies and Tools Related Companies Adverum Biotechnologies Alternatives Cardiol Therapeutics Alternatives Atossa Therapeutics Alternatives Lexeo Therapeutics Alternatives Black Diamond Therapeutics Alternatives Alpha Cognition Alternatives Caribou Biosciences Alternatives Climb Bio Alternatives Biomea Fusion Alternatives TScan Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PMN) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProMIS Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProMIS Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PMN Stock Free PMN Stock Alerts